US FDA Should Regulate Ads Soliciting Mass Tort Suits, Group Says
Executive Summary
Citing deaths and injuries caused when people stopped talking Xarelto in response to advertisements, US Chamber Institute for Legal Reform recommends Congress give FDA authority to halt misleading lawsuit ads.
You may also be interested in...
US FTC Calls Out Personal Injury Rx Ads As Potentially Misleading
The US Federal Trade Commission says the ads may be causing patients to stop taking medications, asks that they include scientifically sound information and be careful using scare tactics.
Product Liability Litigation Playbook: Pros And Cons For Pharma
Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.
Product Liability Suits: Testosterone, Lipitor Grow While Yaz, Pradaxa Settle
2014 saw some big settlements in personal injury suits involving Rx drugs, but it’s unclear whether this is a trend or just situation-specific decision-making, since fierce litigation continues for many other products.